Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

CGEM vs EDIT: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

CGEM Captures Overall Composite Edge (41.0 SELL vs 48.4 HOLD), While EDIT Leads 4–2 on Growth & Valuation Pillars

CGEM Overall Winner 6-Pillar Tally: CGEM 2 – 4 EDIT Matrix Metrics: CGEM 7 – 3 EDIT

As of Nov 16, 2026, Cullinan Therapeutics, Inc. (CGEM) captures the overall head-to-head institutional edge over Editas Medicine, Inc. (EDIT) on higher Unified Composite conviction (41.0/100 SELL vs. 48.4/100 HOLD) after splitting the core matrix 7–3 (led by Valuation Multiples, Profitability & Quality), while EDIT wins 4–2 across the 6-pillar growth and valuation breakdown. CGEM trades at $9.72 (6.7x Forward P/E, 0.0% operating margin) versus EDIT at $1.91 (N/M Forward P/E, -167.0% operating margin).

  • Composite vs. Pillar Nuance: While EDIT currently prints a higher short-term Unified Composite Score (48.4/100 HOLD vs. CGEM 41.0/100 SELL), CGEM captures the overall institutional head-to-head verdict (7–3 matrix metrics and 2–4 across the 6 pillars) due to superior fundamental profitability (0.0% vs. -167.0% operating margin) and revenue trajectory (+0.0% vs. +37.4% YoY).
  • Technical & Structure Timing Caution: CGEM is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 28.9); meanwhile EDIT is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 33.4). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About CGEM vs EDIT
CGEM NASDAQ Head-to-Head Winner
Cullinan Therapeutics, Inc. Common Stock
Biological Products, (No Disgnostic Substances)
$9.72
-5.45% 1D
Market Cap $653.8M
TTM Revenue N/A
Forward P/E 6.7x
Beta / 30D Vol 1.56β · 104% Vol
Unified Composite Score
41.0 / 100 SELL
Tech 25.0 Fund 51.0 Flow 50.0 Mom 59.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -17.2%), weak momentum, RSI 29
RSI-14: 28.9 · SMA20: $13.21 · SMA50: $15.62
EDIT NASDAQ
Editas Medicine, Inc. Common Stock
Biological Products, (No Disgnostic Substances)
$1.91
-12.21% 1D
Market Cap $336.5M
TTM Revenue $50M
Forward P/E N/M
Beta / 30D Vol 2.32β · 102% Vol
Unified Composite Score
48.4 / 100 HOLD
Tech 33.0 Fund 55.0 Flow 69.0 Mom 60.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -7.3%), weak momentum, RSI 33
RSI-14: 33.4 · SMA20: $2.52 · SMA50: $2.61

6-Pillar Scorecard Institutional Category Breakdown (CGEM 2 – 4 EDIT)

Columns: Metric · CGEM · EDIT
1. Valuation Multiples CGEM
Forward P/E 6.7x N/M
Trailing P/E 6.7x N/M
PEG Ratio N/M N/M
EV / Revenue N/M 5.2x
2. Growth & Scale EDIT
Revenue Growth (YoY) +0.0% +37.4%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) N/A $50M
Market Cap $653.8M $336.5M
3. Profitability & Quality CGEM
Gross Margin N/A -73.3%
Operating Margin 0.0% -167.0%
Net Profit Margin 0.0% -144.9%
Return on Equity (ROE) -50.3% -147.4%
4. Balance Sheet & Cash Flow EDIT
Cash Generation (TTM) N/A -$110M
Cash Flow Margin N/A N/A
Net Cash / Leverage $4.33 Book/Sh · -50.3% ROE $79M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning EDIT
Options Structure Phase UNCLASSIFIED BREAKDOWN
Current IV / %ile 124.5% (9th %ile) 95.8% (38th %ile)
Put/Call OI Skew N/A 0.29x (Call-Skewed)
OBV Trend / Tech Phase NEUTRAL · Markdown NEUTRAL · Markdown
6. R&D & Supply-Chain Moat EDIT
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Concentrated Oligopoly Moat
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: CGEM (7) vs EDIT (3)
Institutional Metric CGEM EDIT Criterion Row Edge
Market Capitalization
Scale
$653.8M $336.5M Larger Scale CGEM
Trailing P/E Ratio
Valuation
6.7x N/M Lower Multiple CGEM
Forward P/E Ratio
Valuation
6.7x N/M Lower Multiple CGEM
Revenue Growth (YoY)
Growth
+0.0% +37.4% Higher Growth EDIT
Operating Margin (TTM)
Profitability
0.0% -167.0% Higher Margin CGEM
Net Profit Margin
Profitability
0.0% -144.9% Higher Margin CGEM
Return on Equity (ROE)
Capital Efficiency
-50.3% -147.4% Higher ROE CGEM
52-Week Range Position
Momentum
12% ($8–$23) 11% ($2–$4) Stronger Trend CGEM
Beta / 30D Volatility
Risk Regime
1.56β · 104% Vol 2.32β · 102% Vol Lower Realized Risk EDIT
Unified Institutional Score
Composite Signal
41.0 / 100 (SELL) 48.4 / 100 (HOLD) Higher Composite EDIT
Trailing 12M Revenue (USD)
Operating Scale
N/A $50M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A -73.3% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev N/M PEG · 5.2x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
N/A ($4.33 Book/Sh · -50.3% ROE) -$110M ($79M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon EDIT +5.89 pp
CGEM: -24.83% · EDIT: -18.94%
3M Horizon EDIT +19.51 pp
CGEM: -53.36% · EDIT: -33.85%
6M Horizon EDIT +9.93 pp
CGEM: -34.63% · EDIT: -24.7%
1Y Horizon CGEM +42.53 pp
CGEM: +17.53% · EDIT: -25.0%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on CGEM vs EDIT. Trailing 12-month operating profitability (CGEM 0.0% vs EDIT -167.0%) and valuation multiples (CGEM 6.7x vs EDIT N/M Forward P/E) are benchmarked directly in Pillar 4 below.

CGEM ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-50.3% · 6.7x
EDIT ADR TTM Benchmark FX-Normalized USD
TTM Revenue$50M
Gross Margin-73.3%
Op. Margin-167.0%
ROE / Fwd P/E-147.4% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
CGEM UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 124.5%
IV Percentile 9th %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact CGEM Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
EDIT BREAKDOWN
146d in phase · OBV NEUTRAL
Current IV 95.8%
IV Percentile 38th %ile
Put/Call OI Skew 0.29x (Call-Skewed)
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact EDIT Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
CGEM Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $653.8M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
EDIT Moat Profile Concentrated Oligopoly Moat
Biotechnology Operator
Competes within the Biotechnology value chain with $336.5M market capitalization and -167.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published · CRISPR / Gene Editing

Investor FAQ CGEM vs EDIT Key Questions & Quantitative Answers

As of Nov 16, 2026, Cullinan Therapeutics, Inc. (CGEM) captures the overall head-to-head institutional edge over Editas Medicine, Inc. (EDIT) on higher Unified Composite conviction (41.0/100 SELL vs. 48.4/100 HOLD) after splitting the core matrix 7–3 (led by Valuation Multiples, Profitability & Quality), while EDIT wins 4–2 across the 6-pillar growth and valuation breakdown. CGEM trades at $9.72 (6.7x Forward P/E, 0.0% operating margin) versus EDIT at $1.91 (N/M Forward P/E, -167.0% operating margin). Composite vs. Pillar Nuance: While EDIT currently prints a higher short-term Unified Composite Score (48.4/100 HOLD vs. CGEM 41.0/100 SELL), CGEM captures the overall institutional head-to-head verdict (7–3 matrix metrics and 2–4 across the 6 pillars) due to superior fundamental profitability (0.0% vs. -167.0% operating margin) and revenue trajectory (+0.0% vs. +37.4% YoY). Technical & Structure Timing Caution: CGEM is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 28.9); meanwhile EDIT is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 33.4). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

EDIT leads the Growth & Scale pillar: CGEM posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with EDIT at +37.4% YoY revenue growth and +0.0% YoY earnings growth on $50M TTM revenue (-73.3% gross margin, -167.0% operating margin). On trailing 12-month operating scale, CGEM generates N/A in USD-normalized revenue versus $50M for EDIT. In operating R&D and SG&A reinvestment, CGEM deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for EDIT.

CGEM screens cheaper on headline valuation multiples. CGEM trades at 6.7x Forward P/E, 6.7x Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin), whereas EDIT trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 5.2x EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against CGEM (-50.3% ROE) versus EDIT (-147.4% ROE) capital efficiency.

In options market volatility and institutional positioning, CGEM carries 124.5% implied volatility (9th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.56β · 104% Vol realized risk). By comparison, EDIT carries 95.8% implied volatility (38th %ile, Balanced (25th–60th %ile)), a 0.29x (Call-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (2.32β · 102% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.